BACKGROUND: Cervical dysplasia and tumorigenesis have been linked with numerous chromosomal aberrations. The goal of this study was to evaluate 35 genomic regions associated with cervical disease and to select those which were found to have the highest frequency of aberration for use as probes in fluorescent in-situ hybridization. METHODS: The frequency of gains and losses using fluorescence in-situ hybridization were assessed in these 35 regions on 30 paraffin-embedded cervical biopsy specimens. Based on this assessment, 6 candidate fluorescently labeled probes (8q24, Xp22, 20q13, 3p14, 3q26, CEP15) were selected for additional testing on a set of 106 cervical biopsy specimens diagnosed as Normal, CIN1, CIN2, CIN3, and SCC. The data were analyzed on the basis of signal mean, % change of signal mean between histological categories, and % positivity. RESULTS: The study revealed that the chromosomal regions with the highest frequency of copy number gains and highest combined sensitivity and specificity in high-grade cervical disease were 8q24 and 3q26. The cytological application of these two probes was then evaluated on 118 ThinPrep samples diagnosed as Normal, ASCUS, LSIL, HSIL and Cancer to determine utility as a tool for less invasive screening. Using gains of either 8q24 or 3q26 as a positivity criterion yielded specificity (Normal +LSIL+ASCUS) of 81.0% and sensitivity (HSIL+Cancer) of 92.3% based on a threshold of 4 positive cells. CONCLUSIONS: The application of a FISH assay comprised of chromosomal probes 8q24 and 3q26 to cervical cytology specimens confirms the positive correlation between increasing dysplasia and copy gains and shows promise as a marker in cervical disease progression.
BACKGROUND:Cervical dysplasia and tumorigenesis have been linked with numerous chromosomal aberrations. The goal of this study was to evaluate 35 genomic regions associated with cervical disease and to select those which were found to have the highest frequency of aberration for use as probes in fluorescent in-situ hybridization. METHODS: The frequency of gains and losses using fluorescence in-situ hybridization were assessed in these 35 regions on 30 paraffin-embedded cervical biopsy specimens. Based on this assessment, 6 candidate fluorescently labeled probes (8q24, Xp22, 20q13, 3p14, 3q26, CEP15) were selected for additional testing on a set of 106 cervical biopsy specimens diagnosed as Normal, CIN1, CIN2, CIN3, and SCC. The data were analyzed on the basis of signal mean, % change of signal mean between histological categories, and % positivity. RESULTS: The study revealed that the chromosomal regions with the highest frequency of copy number gains and highest combined sensitivity and specificity in high-grade cervical disease were 8q24 and 3q26. The cytological application of these two probes was then evaluated on 118 ThinPrep samples diagnosed as Normal, ASCUS, LSIL, HSIL and Cancer to determine utility as a tool for less invasive screening. Using gains of either 8q24 or 3q26 as a positivity criterion yielded specificity (Normal +LSIL+ASCUS) of 81.0% and sensitivity (HSIL+Cancer) of 92.3% based on a threshold of 4 positive cells. CONCLUSIONS: The application of a FISH assay comprised of chromosomal probes 8q24 and 3q26 to cervical cytology specimens confirms the positive correlation between increasing dysplasia and copy gains and shows promise as a marker in cervical disease progression.
Authors: Y-W Choi; S M Bae; Y-W Kim; H N Lee; Y W Kim; T C Park; D Y Ro; J C Shin; S J Shin; J-S Seo; W S Ahn Journal: Int J Gynecol Cancer Date: 2007 May-Jun Impact factor: 3.437
Authors: Jack Cuzick; Christine Clavel; Karl-Ulrich Petry; Chris J L M Meijer; Heike Hoyer; Samuel Ratnam; Anne Szarewski; Philippe Birembaut; Shalini Kulasingam; Peter Sasieni; Thomas Iftner Journal: Int J Cancer Date: 2006-09-01 Impact factor: 7.396
Authors: Saskia M Wilting; Jillian de Wilde; Chris J L M Meijer; Johannes Berkhof; Yajun Yi; Wessel N van Wieringen; Boudewijn J M Braakhuis; Gerrit A Meijer; Bauke Ylstra; Peter J F Snijders; Renske D M Steenbergen Journal: Genes Chromosomes Cancer Date: 2008-10 Impact factor: 5.006
Authors: Nancy P Caraway; Abha Khanna; Marilyn Dawlett; Ming Guo; Nina Guo; E Lin; Ruth L Katz Journal: Gynecol Oncol Date: 2008-04-22 Impact factor: 5.482
Authors: Patricia Luhn; Jane Houldsworth; Lynnette Cahill; Mark Schiffman; Philip E Castle; Rosemary E Zuna; S Terence Dunn; Michael A Gold; Joan Walker; Nicolas Wentzensen Journal: Gynecol Oncol Date: 2013-06-13 Impact factor: 5.482
Authors: Susannah La-Touche; Christophe Lemetre; Maryou Lambros; Elzbieta Stankiewicz; Charlotte K Y Ng; Britta Weigelt; Ramzi Rajab; Brendan Tinwell; Cathy Corbishley; Nick Watkin; Dan Berney; Jorge S Reis-Filho Journal: PLoS One Date: 2016-02-22 Impact factor: 3.240
Authors: Enery Lorenzo; Katia Camacho-Caceres; Alexander J Ropelewski; Juan Rosas; Michael Ortiz-Mojer; Lynn Perez-Marty; Juan Irizarry; Valerie Gonzalez; Jesús A Rodríguez; Mauricio Cabrera-Rios; Clara Isaza Journal: Microarrays (Basel) Date: 2015-06